Tower Research Capital LLC (Trc) Relmada Therapeutics, Inc. Transaction History
Tower Research Capital LLC (Trc)
- $3.39 Billion
- Q3 2025
A detailed history of Tower Research Capital LLC (Trc) transactions in Relmada Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,581 shares of RLMD stock, worth $6,244. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,581
Previous 6,189
74.45%
Holding current value
$6,244
Previous $3,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
22 transactions
Others Institutions Holding RLMD
# of Institutions
51Shares Held
7.88MCall Options Held
84.3KPut Options Held
0-
Ikarian Capital, LLC Dallas, TX1.84MShares$7.28 Million0.58% of portfolio
-
Driehaus Capital Management LLC Chicago, IL740KShares$2.92 Million0.01% of portfolio
-
Boothbay Fund Management, LLC New York, NY693KShares$2.74 Million0.02% of portfolio
-
Acadian Asset Management LLC Boston, MA583KShares$2.3 Million0.0% of portfolio
-
Black Rock Inc. New York, NY573KShares$2.26 Million0.0% of portfolio
About RELMADA THERAPEUTICS, INC.
- Ticker RLMD
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,608,500
- Market Cap $113M
- Description
- Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that ...